A benefit-risk assessment of ofloxacin otic solution in ear infection

Drug Safety

Volumn 26, Issue 6, 2003, Pages 405-420

  Wai, Talen K H ^a   Tong, Michael C F ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIINFECTIVE AGENT; BETAMETHASONE; CHLORAMPHENICOL; CLAVULANIC ACID; DEXAMETHASONE; FRAMYCETIN; GENTAMICIN; GRAMICIDIN; HYDROCORTISONE; NEOMYCIN; OFLOXACIN; POLYMYXIN B; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTHROPATHY; BALANCE DISORDER; CLINICAL PRACTICE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG ABSORPTION; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; EAR INFECTION; EXTERNAL OTITIS; HUMAN; KIDNEY DISEASE; META ANALYSIS; MINIMUM INHIBITORY CONCENTRATION; NEUROTOXICITY; NONHUMAN; OTALGIA; OTITIS MEDIA; OTORRHEA; OTOTOXICITY; PERCEPTION DEAFNESS; PREVALENCE; PRIORITY JOURNAL; PSYCHOSOCIAL DISORDER; REVIEW; RISK BENEFIT ANALYSIS; TINNITUS; TYMPANOSTOMY TUBE; VERTIGO; VISUAL IMPAIRMENT;

ADMINISTRATION, TOPICAL; ANTI-INFECTIVE AGENTS; HUMANS; OFLOXACIN; OTITIS; RISK ASSESSMENT;

EID: 0038708262     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200326060-00003     Document Type: Review

References (61)

1. Goldblatt E, Dohar J, Nozza R, et al. Topical versus systemic amoxicillin/clavulanate in purulent otorrhea in children with tympanostomy tubes. Inter J Pediatr Otorhinolaryngol 1998; 46: 91-101
2. Ohyama M, Furuta S, Kazyuyoshi U, et al. Ofloxacin otic solution in patient with oitis media. Arch Otolaryngol Head Neck Surg 1999; 125: 337-40
3. Daiichi Pharmaceutical Corporation, 2002. (Data on file.)
4. Daiichi Pharmaceutical Corporation, 2002. (Data on file.)
5. Floxin Otic (ofloxacin otic solution) 0.3%. Package insert. Daiichi Pharmaceutical Corporation drug prescribing information
6. Hooper DC. Quinolone mode of action-new aspects. Drugs 1994; 45 Suppl. 3: 8-14
7. Simpson KL, Markham A. Ofloxacin otic solution: a review of its use in the management of ear infections. Drugs 1999; 58 (3): 509-31
8. Agro A, Garner ET. Single dose, double-blind, placebo-controlled parallel group study to assess the pharmacokinetics and penetration of ofloxacin otic solution through a tympanostomy tube in adults without active otitis media. Daiichi Pharmaceutical Corporation, 1995, 1996 Study report protocol 82DA-PRT 004. (Data on file)
9. Agro A, Garner ET., McLean PH. Single dose, double-blind, placebo-controlled parallel group study to assess the pharmacokinetics and penetration of ofloxacin otic solution through a tympanostomy tube in adults with suppurative otitis media with otorrhoea. Daiichi Pharmaceutical Corporation, 1995, 1996 Study report protocol 8280-A-PRT 005. (Data on file)
10. National Committee for Clinical laboratory Standards. Performance standards for antimicrobial susceptibility testing. 1993, Vol. 17. Villanova (PA): NCCLS, M100-S7
11. Thomson KS, Sanders CC. The effects of increasing levels of quinolone resistance on in-vitro activity of four quinolones. J Antimicrob Chemother 1998 Aug; 42 (2): 179-87
12. Raza SA, Denholm SW, Wong JC. An audit of the management of acute otitis externa in an ENT casualty clinic. J Laryngol Otol 1995; 109: 130-3
13. Ruben RJ. Efficacy of ofloxacin and other otic preparations for otitis externa. Pediatr Infect Dis J 2001 Jan; 20 (1): 108-10, 120-2
14. Bluestone CD. Epidemiology and pathogenesis of chronic suppurative otitis media: implications for prevention and treatment. Int J Pediatr Otol 1998; 42: 207-23
15. Godinho RN, Goncalves TM, Nunes FB, et al. Prevalence and impact of chronic otitis media in school age children in Brazil. First epidemiologic study concerning chronic otitis media in Latin America. Int J Pediatr Otorhinolaryngol 2001 Dec 1; 61 (3): 223-32
16. Balle VH, Tos M, Dang HS, et al. Prevalence of chronic otitis media in a randomly selected population from two communes in southern Vietnam. Acta Otolaryngol Suppl 2000; 543: 51-3
17. Daly KA, Giebink GS. Clinical epidemiology of otitis media. Pediatr Infect Dis J 2000; 19 (5 Suppl.): S31-6
18. Nelson JD. Chronic suppurative otitis media. Pediatr Infect Dis J 1988; 7: 446-8
19. Department of Health (UK). Hospital Episode Statistics 2002 Dec; 2000/01
20. Debruyne F, Jorissen M, Poelmans J. Otorrhea during trans-tympanal ventilation. Am J Otol 1988 Jul; 9 (4): 316-7
21. Per-Lee JH. Long-term middle ear ventilation. Laryngoscope 1981; 91 (7): 1063-73
22. Jung T, Rhee CK. Otolaryngologic approach to the diagnosis and management of otitis media. Otolaryngologic Clin North Am 1991; 24: 931-45
23. Cantor RM. Otitis externa and otitis media: a new look at old problems. Emerg Med Clin North Am 1995; 13 (2): 445-55
24. Kempthorne J, Giebink G. Pediatric approach to the diagnosis and management of otitis media. Otolaryngologic Clin North Am 1991; 24: 905-29
25. Jones RN, Milazzo J, Seidlin M. Ofloxacin otic solution for treatment of otitis externa in children and adults. Arch Otolaryngol Head Neck Surg 1997; 123 (11): 1193-200
26. Wintermeyer S, Nahata M. Chonic suppurative otits media. Ann Pharmacol 1994; 28: 1089-99
27. Agro AS, Garner ET, Wright JW, et al. Clinical trial of ototopical ofloxacin for treatment of chronic suppurative otitis media. Clin Ther 1998; 20 (4): 744-59
28. Acuin J, Smith A, Mackenzie I. Interventions for chronic suppurative otitis media. Available in The Cochrane Library [data-base on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 2. Oxford: Update Sotware, 2002
29. Esposito S, Noviello S, D'Errico G, et al. Topical ciprofloxacin versus intramuscular gentamicin for chronic otitis media. Arch Otolaryngol Head Neck Surg 1992; 118: 842-4
30. Yuen P, Lau S, Chau P, et al. Ofloxacin eardrop treatment for active chronic suppurative otitis media: prospective randomized study. Am J Otol 1994; 15: 670-3
31. Llorente J, Sabater F, Maristany M, et al. Estudio multicentrico comparativo de la eficacia y tolerancia de ciprofloxacino topico (0.3%) versus gentamicina topica (0.3%) en el tratamiento de la otitis media cronica simple no colesteatomatosa en fase supurativa [Multicenter comparative study of the effectiveness and tolerance of topical ciprofloxacine (0.3%) versus topical gentamicine (0.3%) in the treatment of chronic suppurative otitis media without cholesteatoma]. An Otorrinolaringol Ibero Am 1995; 5: 521-33
32. Tutkun A, Ozagar A, Koc A, et al. Treatment of chronic ear disease: topical ciprofloxacin vs topical gentamicin. Arch Otolaryngol Head Neck Surg 1995; 121: 1414-6
33. Tong MC, Woo JK, van Hasselt CA. A double blind comparative study of ofloxacin otic drops versus neomycin-polymyxin B-hydrocortisone otic drops in the medical treatment of chronic suppurative otitis media. J Laryngol Otol 1996; 110 (4): 309-14
34. Abes G, Espallardo N, Tong M, et al. A systematic review of the effectiveness of ofloxacin otic solution for the treatment of suppurative otitis media. Internal report Daiichi Pharmaceutical Corporation, Feb 2001
35. Boesoirie T. A comparative study between ofloxacin ear drops and neomycin-polymixin b-hydrocortisone ear drops on the chronic suppurative otitis media. Presented at the 9th ASEAN ORL Head & Neck Congress; 2001 Mar 31-Apr 1, Singapore
36. Helmi A, Ratna D, Zainul A, et al. The efficacy and safety of ofloxacin otic solution for active suppurative otitis media. Presented at the 9th ASEAN ORL Head & Neck Congress; 2001 Mar 31-Apr 1, Singapore
37. Subramaniam K, Jalaludin M, Krishnan G. Comparative study of ofloxacin otic drops versus neomycin-polymixin b-hydrocortisone in the medical management of chronic suppurative otitis media. Presented at the 9th ASEAN ORL Head & Neck Congress; 2001 Mar 31-Apr 1, Singapore
38. Abes J, Jamir J, Gloria-Cruz MT, et al. Comparative efficacy and safety of ofloxacin and polymixin otic drops for chronic suppurative otitis media. UPMJ 1998; 4 (1): 59-70
39. Supiyaphun P, Chochaipanichnon L, Tonsakulrungruang K, et al. The treatment of chronic suppurative otitis media and otitis externa with 0.3 per cent ofloxacin otic solution: a clinico-microbiologic study. J Med Assoc Thail 1995; 78 (1): 18-21
40. Gendeh S. A comparative study of ofloxacin otic drops vs framycetin sulfate-dexamethasone-gramicidin otic drops in the medical treatment of otitis externa and chronic suppurative otitis media. Presented at the 9th ASEAN ORL Head & Neck Congress; 2001 Mar 31-Apr 1, Singapore
41. Dohar J, Garner E, Nielsen R, et al. Topical ofloxacin treatment of otorrhea in children with tympanostomy tubes. Arch Otol Head Neck Surg 1999; 125 (5): 537-45
42. Tong MC, Yue V, Ku PK, et al. Preoperative topical ofloxacin solution for tympanoplasty: a randomized, controlled study. Otol Neurotol 2002 Jan; 23 (1): 18-20
43. Gates GA, Avery C, Prihoda TJ, et al. Delayed onset post-tympanotomy otorrhea. Otolaryngol Head Neck Surg 1988 Feb; 98 (2): 111-5
44. Goldblatt EL. Efficacy of ofloxacin and other otic preparations for acute otitis media in patients with tympanostomy tubes. Pediatr Infect Dis J 2001; 20 (1): 116-9
45. Hawkins JE. Drug ototoxicity in Handbook of sensory physiology. Vol 5. Berlin: Springer-Verlag, 1976: 707-48
46. Dreschler WA, van de Hulst RJ, Tange RA, et al. The role of high-frequency audiometry in early detection of ototoxicity. Audiology 1985; 24 (6): 387-95
47. Lundy LB, Graham MD. Ototoxicity and ototopical medications: a survey of otolaryngologists. Am J Otol 1993; 14 (2): 141-6
48. Linder TE, Zwicky S, Brandle P. Ototoxicity of ear drops: a clinical perspective. Am J Otol 1995; 16 (5): 653-7
49. Welling DB, Forrest LA, Goll III F. Safety of ototopical antibiotics. Laryngoscope 1995; 105 (5 Pt 1): 472-4
50. Wong DL, Rutka JA. Do aminoglycoside otic preparations cause ototoxicity in the presence of tympanic membrane perforations? Otolaryngol Head Neck Surg 1997; 116 (3): 404-10
51. Russell PT, Church CA, Jinn TH, et al. Effects of common topical otic preparations on the morphology of isolated cochlear outer hair cells. Acta Otolaryngolog 2001; 121 (2): 135-9
52. Barlow DW, Duckert LG, Kreig CS, et al. Ototoxicity of topical otomicrobial agents. Acta Otolaryngol 1995 Mar; 115 (2): 231-5
53. Halama AR, Wright CG, Meyerhoff WL. Ototoxicity of an ototopic preparation: experimental results and clinical facts. Acta Otorhinolaryngol Belg 1991; 45 (3): 279-82
54. Podoshin L, Fradis M, Ben David J. Ototoxicity of ear drops in patients suffering from chronic otitis media. J Laryngol Otol 1989 Jan; 103 (1): 46-50
55. Bureau of Drug Surveillance health, Canada. The Canadian Adverse Drug Reaction Newsletter 1997 Apr; 7 (2)
56. Christ W, Lehnert T, Ulbrich B. Specific toxicologic aspects of the quinolones. Rev Infect Dis 1988; 10 Suppl. 1: S141-6
57. Kato M, Akahane K, Shimoda K. Lack of chondrotoxicity of ofloxacin otic solution on the auditory ossicle cartilages of juvenile guinea pigs. J Antimicrob Chemother 1997; 39 (2): 269-71
58. Daiichi Pharmaceutical Corporation. 2002. (Data on file.)
59. Daiichi Pharmaceutical Corporation, 2002. (Data on file.)
60. Black HE, Schaefer GJ, Dolan DF, et al. Preclinical study of the ototoxic potential of an otic solution of ofloxacin. Abstract and Poster presented at the 12th Annual Meeting of the American Society of Pediatric Otolaryngology: 1997 May 14-16; Scottsdale (AZ)
61. Gates GA. Safety of ofloxacin otic and other ototopical treatments in animal models and in humans. Pediatr Infect Dis J 2001; 20 (1): 104-7; 120-2